Intravenous and Intracranial GD2-CAR T Cells for H3K27M⁺ Diffuse Midline Gliomas

Arm A of Phase I trial no. NCT04196413 administered one intravenous dose of autologous GD2-CART to patients with H3K27M-mutant pontine or spinal DMG at two dose levels following lymphodepleting chemotherapy.